Digestive cryptosporidiosis (DC) can mimic GVHD after allogeneic haematopoietic stem cell transplantation (HSCT), thus requiring a reduction of immunosuppressive drugs and a specific therapy, whereas GVHD requires an intensification of immunosuppression. We systematically searched for cryptosporidiosis by light microscopy, immunochromatography and PCR in HSCT recipients who presented with at least one episode of diarrhoea. Of 115 consecutive patients allografted between July 2006 and November 2008, we analysed stools in 52 of 56 patients meeting these criteria. We identified Cryptosporidium parvum in 5 of the 52 patients (9.6%) at a median of 503 days (range 20-790) after HSCT. In those five patients, the median CD4 þ cell and B lymphocyte counts were 60/mm 3 (0-234) and 0/mm 3 (0-96), respectively. Two patients died of invasive fungal infections. In the other three patients, diarrhoea disappeared after a median of 5 weeks following onset of bitherapy with azithromycine and nitazoxanide; they were still alive 433, 380 and 1179 days after the DC diagnosis. DC is probably under diagnosed after HSCT because it is difficult to detect during the asymptomatic phase. Early bitherapy and reduction of immunosuppression seem efficacious. In our series, DC has a seasonal pattern and is promoted by profound T lymphopenia.
Introduction
Cryptosporidium spp are enteric apicomplexan protozoa responsible for diarrhoea worldwide. The two major species that infect humans are Cryptosporidium parvum, which is able to infect both humans and animals, and Cryptosporidium hominis, which is more specific to humans. 1 Cryptosporidia infect intestinal epithelial cells causing transient diarrhoea in healthy humans, but causing chronic diarrhoea and sclerosing cholangitis in subjects with AIDS or X-linked immunodeficiency with hyper IgM secretion. 2, 3 Intestinal cryptosporidiosis was previously described in patients with haematological malignancies 4, 5 and in bone marrow transplant recipients, [6] [7] [8] [9] but its precise incidence is unknown. Digestive cryptosporidiosis (DC) can mimic intestinal chronic GVHD. Specific techniques for detecting and identifying cryptosporidiosis in the stools could confirm the diagnosis and accelerate the onset of a specific therapy. Following the detection of two cases of cryptosporidiosis in haematopoietic stem cell transplant (HSCT) recipients during the summer of 2006, we implemented a rapid diagnostic scheme by first using a direct antigen detection followed by staining and molecular detection in all diarrhoeic stools of HSCT recipients.
The aim of the present study is to report the diagnosis, treatment and outcome of DC in HSCT recipients in our centre and to give details of its incidence in this specific prospective cohort.
Patients and methods

Patients
The detection of Cryptosporidium was routinely included in the follow-up of allogeneic HSCT recipients since July 2006, and stools were systematically analysed in the event of diarrhoea. A total of 150 consecutive patients received an allogeneic HSCT between July 2006 and November 2008 in the bone marrow transplantation unit of Jean Minjoz University Hospital (Besanc¸on, France). They were prospectively included in this study and gave their consent for the data analyses. The local ethics committee approved the data collection.
All patients received a T cell unmanipulated graft. GVHD was scored according to Glucksberg et al. 10 All patients were monitored weekly after D15 post-HSCT for the presence of CMV, EBV and the adenovirus genome in blood and every 15 days for the BK virus by PCR in blood and urine. Galactomannan and aspergillus specific PCR in the serum were also checked on a weekly basis in all patients. Ganciclovir treatment was initiated according to a preemptive strategy in the event of CMV identification. 11 Lipid formulations of amphotericin B or voriconazole were also introduced as a preemptive therapy in the event of positive galactomannan or aspergillus PCR. Post transplant recommendations regarding water born infections as cryptosporidiosis were based on the CDC guidelines: exclusive use of boiled/filtered/bottled water, avoidance of swimming or playing in recreational water and washing raw fruits and vegetables with boiled water. 12 Laboratory methods Parasitological analyses. Until July 2006, diagnosis of DC in our centre was based solely on the use of the modified Ziehl-Neelsen acid-fast method for staining of oocytes. Stools were investigated for Cryptosporidium only after a medical prescription. The occurrence of two cases of cryptosporidiosis in July 2006, led us to investigate systematically the diarrhoeic stools of HSCT recipients for Cryptosporidium detection and to implement a new strategy based on the systematic use of an immunochromatographic dipstick (RIDA QUICK, R-Biopharm AG, Darmstadt, Germany). A positive RIDA QUICK was confirmed by the Ziehl-Neelsen acid-fast staining method. PCR genotyping was performed using previously described methods when either method (RIDA QUICK or Ziehl-Neelsen) gave a positive result. 13 Other biological parameters. Gastrointestinal biopsy specimens from HSCT recipients with diarrhoea or vomiting and nausea were examined. Biopsies were systematically analysed using standard cultures for bacteria and fungi. Immunohistochemical procedures were followed for adenovirus and CMV, and MRC5 cell culture was systematically performed for viral detection. Stools were also systematically screened for bacteria, adenovirus, rotavirus and parasites.
All patients were monitored for lymphocyte counts,
þ , B lymphocyte and natural killer cell counts at 1, 3, 6, 12, 18 and 24 months after HSCT. Serum immunoglobulin G, A and M levels were quantified during each outpatient evaluation.
Statistics. The T cell count was compared using the Mann-Whitney bilateral test.
Treatment
Immunosupressive therapies were reduced as soon as the cryptosporidiosis diagnosis was confirmed. Patients were treated with azithromycine 500 mg twice daily associated with nitazoxanide 500 mg twice daily.
Results
A total of 56 patients presented with at least one episode of diarrhoea during the study period, 52 of whom had at least one stool sample analysed for cryptosporidiosis (median of 7 stool sample analyses per patient). DC was diagnosed in five patients. Cryptosporidiosis was diagnosed with the ZiehlNeelsen method in all cases, and by antigen detection in three cases (no. 3, 4, 5). Case 1 was first diagnosed by histological analysis of a gut biopsy sample and confirmed with the Ziehl-Neelsen method. PCR analyses allowed the Cryptosporidium parvum genome to be identified in all patients.
Four patients underwent HSCT from an HLA identical sibling donor and one from a matched unrelated donor. Primary disease, conditioning regimen and the site of cryptosporidiosis infection are shown in Table 1 . GVHD prophylaxis consisted of CsA and MTX for two patients (patient no. 1 received MTX on D1, 3 and 6 and patient no. 2 received MTX on D1, 3, 6 and 11), and CsA and mycophenolate mofetil for patients no. 3, 4 and 5. Clinical symptoms appeared at a median of 503 days (range 20-790) after HSCT and included diarrhoea, vomiting, anorexia and weight loss in all patients. In patient no. 4, diarrhoea appeared during the neutropenic phase just after the conditioning regimen, and on D25 she presented with pancreatitis and cholangitis. She died of a multiple organ dysfunction syndrome related to disseminated candidiasis. Bowel biopsies performed in three patients showed digestive tract GVHD in two of them 1 and 6 months before DC diagnosis (patient no. 1 and no. 3), respectively, and absence of GVHD in patient no. 2.
All patients with DC diagnosis had a profound humoral and cellular immunodeficiency. In those patients, the median cell count was CD4 60/mm 3 (0-234), B cell 0/mm 3 (0-96) and the median IgG level was 3.9 g/L (2.2-5.2). Details of the immunological status of DC patients and co-infections are shown in Table 2 . At the same time point (median 503 days after HSCT), the patients without DC had significantly higher CD4 counts (P ¼ 0.005; median 496/mm 3 , range 40-3400). In all cases, the first clinical symptoms occurred between July and December of each year (2006) (2007) (2008) . A treatment associating azithromycine and nitazoxanide was started after the diagnosis of DC was confirmed. A clinical response was obtained after a median of 5 (4-6) weeks with a negativation of Cryptosporidium specific PCR in the stools. The median CD4 number increased to a median of 513 (133-615) at the end of therapy. Three patients were still alive 380, 433, and 1179 days after HSCT and two died from an invasive fungal infection (Scopularopsis acremonium pneumonia in patient 1 and Candida albicans septicaemia in patient 4).
Discussion
The present study reports on the diagnosis, treatment and outcome of DC infection in five patients who received an Digestive cryptosporidiosis in HSCT F Legrand et al allogeneic HSCT and were treated with a bitherapy including nitazoxanid and azithromycine. Diarrhoea, anorexia, nausea and vomiting were the initial symptoms in five cases and in one patient these clinical signs were associated with pancreatitis and cholangitis. Diagnosis of DC in HSCT recipients was hampered by the risk of confusion between digestive GVHD and DC; moreover, three of the five patients described here had a chronic limited mouth and ophthalmic GVHD at DC onset, and one patient presented histological signs of digestive tract GVHD 6 months before DC diagnosis. To overcome this difficulty, we defined a new non-invasive and repeatable diagnostic procedure by systematically using an immunochromatographic dipstick for all diarrhoeic stools of HSCT recipients. When positive, this was followed by staining of oocytes using the Ziehl-Neelsen method. The Rida Quick Cryptosporidium test is performed with a 100% specificity and an 88% sensitivity.
14 This test is more sensitive than conventional microscopical methods. The false-negative coproantigen test is associated with low parasite densities; however, our immunocompromised patients usually have high parasite densities. This test could thus be useful in addition to microscopy when only a single stool sample is available for HSCT outpatients. We completed these analyses by PCR in the event of discrepancies between the RIDA QUICK test and staining and/or for confirmation and identification of the Cryptosporidium genotype when both tests were positive. As proposed in immunocompromised children, the systematic use of PCR in HSCT recipients might contribute to an earlier diagnosis of DC. 15 Immunity against Cryptosporidium relies on cellular and humoral host responses, 16, 17 the main role of CD4 þ T cells being illustrated in AIDS patients. 2 In our series, DC occurred in the context of profound cellular and humoural immunodeficiency in all patients, despite none having received ATG as part of the conditioning regimen or to treat active GVHD.
We found five cases of DC in HSCT recipients from 2006 to 2008, whereas only few patients with DC have been described in previous publications since 1986. [6] [7] [8] [9] In our experience of systematic screening of symptomatic patients, the cumulative incidence of DC in allogeneic HSCT reaches 9.6% in patients with diarrhoea and 4% in the total number of HSCT recipients. Between August and October 2009, we registered two further cases of DC among the first 30 HSCT recipients, thus confirming this proportion. The rural areas and several farms surrounding our centre could represent a risk factor and this high incidence may not be found in other centres, depending on local ecology factors, including contact with calves and with untreated or recreational water. 18, 19 Three of five patients were diagnosed with DC when they were outpatients, and two patients were hospitalized at the time of diagnosis. This upward trend in cryptosporidiosis 20 In particular, we noticed two additional cases of DC between August and October 2009 among non-transplant patients suffering from haematological malignancies and receiving immunosuppressive chemotherapy (one lymphoma and one myeloma, data not shown).
Different drugs have an anti-cryptosporidal activity including paramomycin, spiramycin and nitazoxanide. 21 We chose to treat the patients with an association of azithromycin and nitazoxanide, aiming for a rapid combined action in these fragile immunocompromised patients. The treatment of DC by nitazoxanide has in vitro activity against a variety of microorganisms, including protozoa, helminths and C. parvum or Giardia lamblia in immunocompetent adults and children. 22 This drug has been used previously in the treatment of DC in AIDS patients. 2 Antibiotic therapy for DC is not effective without an appropriate immune restoration. 23 In HSCT recipients, a combination of antimicrobial therapy and tapering of immunosuppressive drugs is necessary to restore immune response and to eradicate the protozoa.
This study emphasises the need for strengthened surveillance and screening of cryptosporidiosis in SCT recipients, especially when severely immunocompromised after transplantation. Larger epidemiological studies are required to confirm our findings and to better identify environmental and patient-dependent risk factors for DC after SCT. We recommend screening for DC in all allogeneic HSCT recipients with digestive symptoms, particularly during the summer and autumn and in the event of GVHD.
